|
|
|
|
Rushing early development without planning for commercialization can lead to delays. Aligning process and analytical strategies from the start supports efficient scale-up and smoother manufacturing.
|
|
|
|
|
Judging cell line development by time to cell bank misses what determines long-term viability. With bispecifics and other complex formats, early decisions on DNA design, clone selection, and regulatory evidence shape how well a program survives scale-up and review.
|
|
|
|
|
A fast timeline to a cell bank can hide weaknesses that surface only in process development or GMP manufacturing. Judging clones on manufacturability, product quality, stability, and traceable history matters most for complex modalities with multi-chain or fusion architectures.
|
|
|
|
|
Accelerated cell line development delivers high-titer biologics in weeks, supporting diverse modalities with robust analytics, scalable productivity, and proven stability across 60+ generations.
|
|
|
|
|
|
|
Accelerate biotherapeutic development with integrated workflows. Learn how early stable pools and advanced vectors decouple material generation from clone selection, de-risking clinical scale-up.
|
|
|
|
|
|
|
Cell line development often sets the pace for reaching IND, sometimes taking up to a year. An integrated approach built around early stable pools, parallel downstream work, and consistent scale-up aims to remove delays between cell line and GMP.
|
|
|
